Skip to content

Research Study Examining Nerve Block for Migraine

Greater Occipital Nerve (GON) Block for Migraine

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00203346
Enrollment
30
Registered
2005-09-20
Start date
2005-06-30
Completion date
Unknown
Last updated
2009-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

Migraine and the skin sensitivity that accompanies it can go away in minutes after a nerve block, which is a procedure involving an injection of a small amount of a local anesthetic next to a nerve to the skin, causing an area of skin to become numb. We have also noticed that light sensitivity goes away quickly after a nerve block. We would like to see how quickly this happens and how long the benefit of nerve block lasts. We are interested to see if these effects are due to the injection itself or due to the lidocaine. A subject may be asked to participate in this study if a subjects physician has planned for a subject to receive an injection of BOTOX® in the area of the Greater Occipital Nerve (a spinal nerve located at the back of the head) as part of a subjects routine preventive treatment for migraine today.

Interventions

Sponsors

Thomas Jefferson University
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subjects with episodic or transformed migraine age 18to 80 years old. * Subjects must have unilateral migraine headache and trigeminal distribution brush allodynia at the time of injection. * Subjects must be able to consent or assent to the study.

Exclusion criteria

* Subjects who in their own or in the investigator's opinion are unable to report the severity of four symptoms (pin sharpness to determine efficacy of nerve block, headache severity, photophobia severity and allodynia severity), every 30 seconds for 5 minutes post injection; * Subjects with skull defect, or history of injury to the area of the GON. * Subjects with prior adverse reaction to GON block, lidocaine or marcaine. * Subjects who are pregnant or lactating

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026